DermBiont
Financing Round
- Series A
Round Led by Symbiosis
DermBiont’s mission is to become the world’s leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. DermBiont’s biotherapeutics discovery team leverages computational biology and a proprietary bioinformatics platform to identify clinically meaningful dysbiosis related to common skin diseases, and mines a curated library of microbes to build a pipeline of products to treat identified dysbiosis across indications. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and with biotherapeutics that repair imbalances of the microbiome.
View Website
Modalities
- Biologic
- Small Molecule
Indications
- Dermatology
- Oncology
Development Status
- Phase 2